Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 74 clinical trials
SELUTION SLR™ 014 In-stent Restenosis

treatment with either the SELUTION SLR™ DEB or SOC to include contemporary DES (zotarolimus-eluting stents and everolimus-eluting stents only) or non-DEB BA. A maximum of 418 randomized subjects will be

unstable angina
infarct
non-target
angina pectoris
in stent restenosis
  • 0 views
  • 23 Apr, 2022
  • 1 location
Arteriovenous Fistulae: Drug-eluting Balloon Angioplasty (FAVABED)

Dysfunctions such as tight stenosis or thrombosis in haemodialysis vascular accesses are the leading cause of hospitalisationand morbidity in chronic haemodialysis patients incurring significant related costs estimated at over one billion dollars in the USA. Dysfunctions of these vascular accesses are generally treated by conventional angioplasty as this is the …

  • 1 views
  • 24 Feb, 2022
  • 8 locations
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

there is a need for improving chemotherapy regimen for metastatic G3 NEC of GEP and Unknown origin and this goal may be achieved through more "personalized" chemotherapy regimen.the hypothesis is that mFOLFIRINOX regimen could be a good candidate for challenging the platinum-etoposide regimen in patients with metastatic G3 NEC of …

  • 4 views
  • 27 Apr, 2021
  • 6 locations
LIFE-BTK Randomized Controlled Trial (LIFE-BTK)

Pre-market clinical evaluation of the everolimus eluting Esprit™ BTK System for the planned treatment of narrowed infrapopliteal lesions.

  • 100 views
  • 07 Jun, 2022
  • 54 locations
Phase 1 / 2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (AMEERA-1)

recommended dose (RD) of amcenestrant administered as monotherapy and in combination with palbociclib To assess the incidence rate of DLT and determine the RD of everolimus or abemaciclib in

endocrine therapy
exemestane
measurable disease
metastasis
estrogen receptor
  • 914 views
  • 06 Jun, 2022
  • 28 locations
Phase 1 / 2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (AMEERA-1)

recommended dose (RD) of amcenestrant administered as monotherapy and in combination with palbociclib To assess the incidence rate of DLT and determine the RD of everolimus or abemaciclib in

endocrine therapy
aromatase inhibitor
palbociclib
exemestane
measurable disease
  • 14 views
  • 27 May, 2022
  • 27 locations
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study (STOPDAPT-3)

bleeding events after percutaneous coroanry intervention (PCI) using cobalt-chromium everolimus-eluting stents (CoCr-EES, XienceTM) in patients with high bleeding risk or under the acute coronary syndrome

acute coronary syndrome
percutaneous coronary intervention
everolimus
aspirin
clopidogrel
  • 0 views
  • 23 Apr, 2022
  • 1 location
ABILITY Diabetes Global

) versus XIENCE Everolimus-Eluting Stents (EES). At least 40% of patients are expected to be affected by multivessel coronary artery disease and 30% with acute coronary syndrome

diabetes mellitus
hypoglycemic agents
angina pectoris
stable angina
percutaneous coronary intervention
  • 0 views
  • 25 Jan, 2021
  • 86 locations
Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels (TRANSFORM II)

) compared to one of the gold standard treatment for native vessel disease (everolimus-eluting stent, EES).

sirolimus
percutaneous coronary intervention
everolimus
angiography
  • 0 views
  • 15 Jun, 2022
  • 9 locations
Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES (PARTHENOPE)

safety and efficacy of the Cre8 amphilimus-eluting stent (Cre8 AES, Alvimedica, Instanbul, Turkey) in comparison with the biodegradable polymer everolimus-eluting stent (Synergy EES, Boston Scientific

percutaneous coronary intervention
everolimus
arterial disease
dapt
antiplatelet therapy
  • 11 views
  • 21 Feb, 2022
  • 12 locations